At the 18th International Conference on Malignant Lymphoma (18ICML) and the European Hematology Association 2025 (EHA2025), multiple clinical trials presented new data on treatments for various lymphoma subtypes. Key findings include the phase III POLARGO trial demonstrating that Pola-R-GemOx improved median overall survival (OS) to 19.5 months compared to 12.5 months with R-GemOx in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). The phase III GOLSEEK-1 study is evaluating golcadomide plus R-CHOP versus placebo plus R-CHOP in untreated high-risk large B-cell lymphoma with progression-free survival (PFS) as the primary endpoint. The ATALANTA-1 study of GLPG5101, a fresh, stem-like CD19 CAR T-cell therapy, showed complete response (CR) and minimal residual disease (MRD) rates of 91% and 100%, respectively, in R/R indolent non-Hodgkin lymphoma (NHL). The phase Ib trial of JNJ-90014496, a CD19/CD20 bispecific CAR T-cell therapy in R/R large B-cell lymphoma (LBCL), reported an overall response rate (ORR) of 95% and CR rate of 80% at the recommended phase 2 dose. The phase III ALPINE trial showed zanubrutinib had superior 36-month PFS (67.4%) and ORR (88.4%) compared to ibrutinib (56.3% PFS, 76.6% ORR) in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The SEQUOIA trial of zanubrutinib plus venetoclax in treatment-naïve CLL/SLL reported a 24-month PFS of 92% and peripheral blood undetectable MRD rate of 59%. The phase III STARGLO trial found glofitamab plus GemOx reduced the risk of progression or death by 59% and showed superior overall survival compared to rituximab plus GemOx in R/R DLBCL, with median OS not reached versus 13.5 months. Other notable studies included the VALYM trial of valemetostat monotherapy in R/R follicular lymphoma (ORR 62%, CR 20%), the VERLen trial of tafasitamab, lenalidomide, and rituximab in elderly DLBCL patients (overall metabolic response at cycle 3 of 72%), and the POLARIS study of orelabrutinib, lenalidomide, and rituximab in mantle cell lymphoma (ORR 97%, CR 69%). These findings reflect ongoing advances in targeted therapies, CAR T-cell treatments, and combination regimens across lymphoma subtypes.